The aim of this symposium is to provide a forum to discuss whether Progressive multifocal leukoencephalopathy (PML) that has been seen in multiple drug trials is a direct consequence of the mechanism of therapeutic action or whether it’s an off-target adverse effect of the therapeutic agent. Progressive multifocal leukoencephalopathy (PML) is a rare, but fatal disease that leads to severe brain inflammation and neural demyelination for presenting patients. This disease is caused by the JC Virus, a polyomavirus generally widespread but latent in human populations. While rare in the general population, the prevalence of PML is increased in HIV patients and notably, has recently been associated with several immunomodulating drug therapies. In order to gain broader perspective on PML and JC virus biology, the impact on clinical practice, and associated regulatory issues, this one day symposium will bring together experts from academia and medicine as well as representatives from drug discovery and the FDA for an interactive series of discussions.
Image credit: Mark Cohen
Networking Reception to Follow